Amylyx Pharmaceuticals (AMLX)
(Real Time Quote from BATS)
$1.94 USD
-0.03 (-1.52%)
Updated Jul 29, 2024 11:18 AM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Amylyx Pharmaceuticals, Inc. [AMLX]
Reports for Purchase
Showing records 1 - 20 ( 31 total )
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 2 Validated Avexitide Open Opportunities in Metabolic Disorder Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Calpain is a Well Validated Target for ALS and other Neurodegenerative Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Interim HELIOS Data Encouraging, Supports C-Peptide as a Surrogate Endpoint in Wolfram
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Positive Biomarker Data from HELIOS has the Potential to Restore Confidence in AMX0035
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
From the Ashes of Phoenix a New Focus Rises in Wolfram Syndrome and PSP; Reiterate Buy and PT Down to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Investment in Developing ALS Biomarker Panel Important for Company?s Dominance in the ALS Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for AMLX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Relyvrio Discontinuation Rate at Par or Better Than Competitors; Reiterate Buy and PT Down to $42
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Negative Opinion on AMX0035 Shows Challenges with CHMP?s Assessment of Neurology Disease Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Acces Compassionnel Coupled with Real World Safety Data Encouraging Ahead of CHMP Decision
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Amylyx Has A Stronger Case Over Other Drugs Approved Under CMA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Thoughts on the Next Steps Post CHMP?s Regulatory Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Thoughts on AMX0114, An Anti-Sense Oligo Targeting Calpain-2; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Importance of Real World Evidence in Drug Approvals-Insights From AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Relyvrio Survival Data is Key for Encouraging Launch; Reit. Buy and PT $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Broadening Payer Coverage by 1H23 Might Be the Growth Driver For Relyvrio
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Snapshot of Novel Targets in Parkinson?s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Focusing on Calpain-2 As the Launch Continues to Get Underway; Reit Buy and PT $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A